Abstract
Sepsis is a complex, multifactorial syndrome that can develop into conditions of different severity, described as septic shock or severe sepsis. In spite of the great progress in understanding the mechanisms involved in the pathogenesis and management of sepsis, only a few therapeutic strategies were able to show a decrease in the mortality from septic shock. Although sepsis consists on a systemic inflammatory response, the anti-inflammatory therapies have failed to improve the outcome of critically ill patients. Here the role of gastrin-releasing peptide in immune processes is reviewed and the data that have prompted the recent patent for GRP receptor antagonists RC-3095 as a therapeutic agent on inflammatory conditions are described.
Keywords: Bombesin, gastrin-releasing peptide, GRP, GRPR, sepsis
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Related Books
Computer-Aided Drug Discovery Methods: A Brief Introduction
Infectious Diseases
Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product
Marine Biopharmaceuticals: Scope and Prospects
COVID 19 – Monitoring with IoT Devices
Frontiers in Clinical Drug Research: Anti-Infectives
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents
Frontiers in Drug Design and Discovery
Recent Trends and The Future of Antimicrobial Agents - Part 2
3